One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
From what we can see, insiders were net buyers in Verve Therapeutics, Inc.'s (NASDAQ:VERV ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.
從我們可以看到的情況來看,內部人士在過去12個月內在Verve Therapeutics, Inc.(納斯達克:VERV)是淨買入的。即,內部人士購買的股票數量大於他們出售的數量。
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
雖然我們認爲股東不應僅僅跟隨內部人士的交易,但邏輯告訴我們,應該注意內部人士是購買還是出售股票。
Verve Therapeutics Insider Transactions Over The Last Year
Verve Therapeutics內部交易情況(過去一年)
In the last twelve months, the biggest single purchase by an insider was when President Andrew Ashe bought US$476k worth of shares at a price of US$6.26 per share. So it's clear an insider wanted to buy, at around the current price, which is US$6.47. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider bought shares at close to current prices. Andrew Ashe was the only individual insider to buy shares in the last twelve months.
在過去的十二個月中,內部人士的最大單筆購買是在董事長安德魯·阿什(Andrew Ashe)以每股6.26美元的價格購買了價值47.6萬美元的股票。因此,很明顯,有一位內部人士希望以目前的價格(6.47美元)買入。當然,他們可能會改變主意。但這表明他們對前景持樂觀態度。雖然我們總是希望看到內部人士買入,但如果購買是在價格低得多的情況下進行的,那麼意義就會降低,因爲他們所看到的機會可能已經過去。在這種情況下,我們很高興地報告,內部人士以接近當前價格買入了股票。安德魯·阿什是過去十二個月中唯一買入股票的內部人士。
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
以下是公司和個人過去12個月的內部交易的可視化描述。如果單擊圖表,您可以查看所有個人交易,包括股票價格、個人和日期!
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
內部人士正在購買的股票是無數的。如果您喜歡投資於較少知名公司,您可以查看此免費的公司列表(提示:內部人士一直在購買它們)。
Insider Ownership
內部人員持股情況
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 5.3% of Verve Therapeutics shares, worth about US$29m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
測試公司領導者與其他股東之間是否一致的另一種方法是查看他們擁有多少股票。 高比例的內部持股通常會使公司領導層更加關注股東的利益。 內部人士擁有5.3%的Verve Therapeutics股票,價值約2900萬美元。 我們確實在其他地方看到過更高的內部持股比例,但這些持股足以表明內部人士與其他股東之間的對齊。
So What Do The Verve Therapeutics Insider Transactions Indicate?
那麼,Verve Therapeutics的內部交易表明了什麼?
The fact that there have been no Verve Therapeutics insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in Verve Therapeutics and we see no evidence to suggest they are worried about the future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 4 warning signs for Verve Therapeutics you should be aware of, and 1 of these shouldn't be ignored.
最近沒有Verve Therapeutics的內部交易,顯然並不讓我們擔憂。 但在過去一年中,內部人士對這隻股票表現出更多的興趣。 內部人士擁有Verve Therapeutics的股份,我們沒有證據表明他們對未來感到擔憂。 了解內部人士的持股和交易情況固然重要,但我們也確保在做出任何投資決策之前,考慮到股票面臨的風險。 舉個例子:我們發現有4個警告信號是你應該關注的,而其中1個不容忽視。
But note: Verve Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:Verve Therapeutics 可能不是最值得買入的股票。因此,請查看這份免費的有趣公司名單,這些公司具有高roe和低負債。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。